[go: up one dir, main page]

PE69299A1 - Compuestos calciliticos - Google Patents

Compuestos calciliticos

Info

Publication number
PE69299A1
PE69299A1 PE1998000256A PE00025698A PE69299A1 PE 69299 A1 PE69299 A1 PE 69299A1 PE 1998000256 A PE1998000256 A PE 1998000256A PE 00025698 A PE00025698 A PE 00025698A PE 69299 A1 PE69299 A1 PE 69299A1
Authority
PE
Peru
Prior art keywords
alkyl
link
formula
compound
optionally replaced
Prior art date
Application number
PE1998000256A
Other languages
English (en)
Inventor
Pradip Kumar Bhatnagar
Robert M Barmore
James Francis Callahan
Mar Eric G Del
Maria Amparo Lago
Thomas The Nguyen
Derek Sheehan
Linda Sue Southhall
Robert Lawrence Smith
Wagenen Bradford C Van
William M Bryan
Joelle Lorraine Burges
Raul Rolando Calvo
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of PE69299A1 publication Critical patent/PE69299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/06—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and unsaturated carbon skeleton
    • C07C255/07—Mononitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/17—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO ARILALQUILAMINICO DE FORMULA I, Y1 ES UN ENLACE, ALQUILENO O ALQUENILENO C1-C4 OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4; Y2 ES METILENO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4 O CF3; Z ES UN ENLACE, O, S, NH, O(CH2)n, C=ONR`'', ENTRE OTROS; R''' ES ALQUILO C1-C4; n ES 1-3; R3 Y R4 SON METILO, ETILO O JUNTOS FORMAN CICLOPROPILO; R5 ES FENILO O NAFTILO OPCIONALMENTE SUSTITUIDO CON OH, CH(CH3)2, OSO2RIV, ENTRE OTROS; RIV ES ALQUILO C1-C4 O CICLOALQUILO C3-C6; G ES UN ENLACE, CR6; R6 ES H, OH; R7 ES H, OH u O-ALQUILO C1-C4; R8 ES H, ALQUILO C1-C4 O R7 Y R8 FORMAN UN CARBONILO; -A-B- ES CH2CH2, UN ENLACE, -CH=CH-; X ES UN GRUPO DE FORMULA (Ia), (Ib), (Ic), (Id), (Ie), QUE CORRESPONDE A FENILO SUSTITUIDO O CONDENSADO CON 2 ANILLOS. TAMBIEN SE REFIERE A UN COMPUESTO DE FORMULA (II), R9 ES H, OH, OCH3, ENTRE OTROS; R10 ES H, Cl, F, CF3 Y CH3 O R9 Y R10 FORMAN UN ANILLO DE FENILO CONDENSADO OPCIONALMENTE SUSTITUIDO; R11 ES METILO, H o F. UN COMPUESTO PREFERIDO ES (R)-3-[2-CIANO-4-[N-BENCIL-N-[4-METILFENILSULFONIL]-AMINO]FENOXI]-1-[1,1-DIMETIL-2-(4-METOXIFENIL)ETILAMINO]-PROPAN-2-OL; ENTRE OTROS. EL COMPUESTO DE FORMULA I PUEDE SER UTIL PARA TRATAR UNA ENFERMEDAD O UN TRASTORNO CARACTERIZADO POR UNA HOMEOSTASIS ANOMALA DE HUESOS O MINERALES; COMO OSTEOPOROSIS, OSTEOSARCOMA, CURACION DE FRACTURAS
PE1998000256A 1997-04-08 1998-04-06 Compuestos calciliticos PE69299A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4272497P 1997-04-08 1997-04-08
US6132797P 1997-10-08 1997-10-08
US6133197P 1997-10-08 1997-10-08
US6133397P 1997-10-08 1997-10-08
US6132997P 1997-10-08 1997-10-08
US6133097P 1997-10-08 1997-10-08

Publications (1)

Publication Number Publication Date
PE69299A1 true PE69299A1 (es) 1999-09-26

Family

ID=27556439

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000256A PE69299A1 (es) 1997-04-08 1998-04-06 Compuestos calciliticos

Country Status (24)

Country Link
US (1) US6294531B1 (es)
EP (1) EP0973730B1 (es)
JP (1) JP2001523223A (es)
KR (1) KR20010006113A (es)
CN (1) CN1259120A (es)
AR (1) AR016510A1 (es)
AT (1) ATE269300T1 (es)
AU (1) AU721910B2 (es)
BR (1) BR9808491A (es)
CA (1) CA2286454A1 (es)
CO (1) CO4950536A1 (es)
DE (1) DE69824566T2 (es)
DZ (1) DZ2461A1 (es)
ES (1) ES2223126T3 (es)
HU (1) HUP0001494A3 (es)
IL (1) IL132205A0 (es)
NO (1) NO994877L (es)
NZ (1) NZ500055A (es)
PE (1) PE69299A1 (es)
PL (1) PL336097A1 (es)
TR (1) TR199902516T2 (es)
TW (1) TW407144B (es)
UY (1) UY24949A1 (es)
WO (1) WO1998045255A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
WO2000048603A1 (en) * 1999-02-17 2000-08-24 Merck & Co., Inc. DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7112594B2 (en) 2000-08-09 2006-09-26 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
AU2001277752A1 (en) 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
ATE343390T1 (de) * 2000-10-25 2006-11-15 Smithkline Beecham Corp Kalzilytische verbindungen
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
TWI316511B (en) * 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
SI1619180T1 (sl) 2003-04-23 2010-04-30 Japan Tobacco Inc Antagonist CaSR
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
SI1877379T1 (sl) 2005-04-13 2013-05-31 Astex Therapeutics Limited Derivati hidroksibenzinamida in njih uporaba kot inhibitorji HSP90
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8779132B2 (en) 2006-10-12 2014-07-15 Astex Therapeutics Limited Pharmaceutical compounds
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
AU2007354000A1 (en) * 2007-05-29 2008-12-04 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN116574039B (zh) * 2023-05-17 2025-02-28 上海大学 一种多取代胺基苯甲腈类化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (es)
GB1199037A (en) 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
GB1199632A (en) * 1967-09-07 1970-07-22 Ici Ltd Alkanolamine Derivatives
US4165384A (en) 1974-11-01 1979-08-21 Aktiebolaget Hassle Amide substituted phenoxy propanol amines
US5166218A (en) 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4017019A1 (de) * 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
ATE298739T1 (de) * 1996-04-09 2005-07-15 Nps Pharma Inc Calcylitische verbindungen

Also Published As

Publication number Publication date
ES2223126T3 (es) 2005-02-16
TR199902516T2 (xx) 2000-02-21
IL132205A0 (en) 2001-03-19
NO994877D0 (no) 1999-10-07
KR20010006113A (ko) 2001-01-26
CA2286454A1 (en) 1998-10-15
AU721910B2 (en) 2000-07-20
CO4950536A1 (es) 2000-09-01
DZ2461A1 (fr) 2003-01-18
UY24949A1 (es) 2001-04-30
BR9808491A (pt) 2000-05-23
EP0973730A4 (en) 2000-08-23
NO994877L (no) 1999-10-07
DE69824566D1 (de) 2004-07-22
NZ500055A (en) 2001-12-21
HUP0001494A2 (hu) 2000-10-28
ATE269300T1 (de) 2004-07-15
HUP0001494A3 (en) 2002-01-28
DE69824566T2 (de) 2005-08-18
WO1998045255A1 (en) 1998-10-15
AU6890098A (en) 1998-10-30
CN1259120A (zh) 2000-07-05
US6294531B1 (en) 2001-09-25
EP0973730B1 (en) 2004-06-16
PL336097A1 (en) 2000-06-05
JP2001523223A (ja) 2001-11-20
EP0973730A1 (en) 2000-01-26
AR016510A1 (es) 2001-07-25
TW407144B (en) 2000-10-01

Similar Documents

Publication Publication Date Title
PE69299A1 (es) Compuestos calciliticos
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
PT971878E (pt) Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
MX9600484A (es) Anhidrato de clorhidrato de paroxetina y procedimiento para su preparacion.
BR9813360A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp)
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
FR2802533B1 (fr) Phenoxypropanolamines, leur preparation et leur application en therapeutique
DE60329073D1 (de) Edg-rezeptoragonisten
AR038882A1 (es) Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene
BR9913255A (pt) Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
PE20040762A1 (es) Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
BR0210285A (pt) Utilização de um composto, composto e composição farmacêutica
PE20021083A1 (es) Moduladores de los receptores estrogenos
PE27497A1 (es) Derivados de 1,5 benzodiazepina
PE122899A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos y procedimientos para su preparacion
IL125960A0 (en) Novel sulphur derivatives comprising an amide bond method for preparing same use thereof as drugs and pharmaceutical compositions containing such derivatives
BR0011339A (pt) Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ES2194709T3 (es) Procedimiento para preparar carbamatos de tetrahidrotiopiran-o-fluorados.
PE20050328A1 (es) Combinaciones de un bisfosfonato y un inhibidor de catepsina k

Legal Events

Date Code Title Description
FC Refusal